The number of active drug shortages has declined sharply since June, according to the FDA’s database.
As of March 19, 76 drugs are in shortage, down from 194 in mid-June.
The database is updated daily to reflect manufacturing recoveries, regulatory actions and how shortages are classified — not solely day-to-day availability at the hospital level.
Here are six recent drug shortages, according to the FDA database:
- Ursodiol capsules: Strides Pharma discontinued the 300 mg presentation as a business decision April 6.
- Idelalisib tablets: Gilead Sciences discontinued 100 mg and 150 mg Zydelig tablets due to manufacturing decisions April 7.
- Fosaprepitant dimeglumine injection: Fresenius Kabi discontinued the 150 mg/5 mL formulation April 8.
- Aprepitant oral powder for suspension: Merck discontinued the 125 mg Emend formulation, with discontinuation expected around November 2026.
- Azithromycin tablets: Pfizer discontinued 500 mg and 250 mg Zithromax tablets April 9.
- Nitrofurantoin oral suspension: Amneal Pharmaceuticals discontinued the 25 mg/5 mL formulation April 10.
